Recombinant human islet amyloid polypeptide forms shorter fibrils and mediates β-cell apoptosis via generation of oxidative stress
- 16 November 2017
- journal article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 474 (23), 3915-3934
- https://doi.org/10.1042/bcj20170323
Abstract
Protein misfolding and aggregation play an important role in many human diseases including Alzheimer's, Parkinson's and type 2 diabetes mellitus (T2DM). The human islet amyloid polypeptide (hIAPP) forms amyloid plaques in the pancreas of T2DM subjects (>95%) that are involved in deteriorating islet function and in mediating β-cell apoptosis. However, the detailed mechanism of action, structure and nature of toxic hIAPP species responsible for this effect remains elusive to date mainly due to the high cost associated with the chemical synthesis of pure peptide required for these studies. In the present work, we attempted to obtain structural and mechanistic insights into the hIAPP aggregation process using recombinant hIAPP (rhIAPP) isolated from Escherichia coli. Results from biophysical and structural studies indicate that the rhIAPP self-assembled into highly pure, β-sheet-rich amyloid fibrils with uniform morphology. rhIAPP-mediated apoptosis in INS-1E cells was associated with increased oxidative stress and changes in mitochondrial membrane potential. The transcript levels of apoptotic genes - Caspase-3 and Bax were found to be up-regulated, while the levels of the anti-apoptotic gene - Bcl2 were down-regulated in rhIAPP-treated cells. Additionally, the expression levels of genes involved in combating oxidative stress namely Catalase, SOD1 and GPx were down-regulated. rhIAPP exposure also affected glucose-stimulated insulin secretion from isolated pancreatic islets. The aggregation of rhIAPP also occurred significantly faster when compared with that of the chemically synthesized peptide. We also show that the rhIAPP fibrils were shorter and more cytotoxic. In summary, our study is one among the few to provide comprehensive evaluation of structural, biophysical and cytotoxic properties of rhIAPP.This publication has 55 references indexed in Scilit:
- Mechanisms of islet amyloidosis toxicity in type 2 diabetesFEBS Letters, 2013
- IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030Diabetes Research and Clinical Practice, 2011
- Islet Amyloid Polypeptide, Islet Amyloid, and Diabetes MellitusPhysiological Reviews, 2011
- Evidence for Proteotoxicity in β Cells in Type 2 Diabetes: Toxic Islet Amyloid Polypeptide Oligomers Form Intracellularly in the Secretory PathwayThe American Journal of Pathology, 2010
- Adherence to a Mediterranean-type diet and reduced prevalence of clustered cardiovascular risk factors in a cohort of 3204 high-risk patientsEuropean Journal of Preventive Cardiology, 2008
- Islet Amyloid in Type 2 Diabetes, and the Toxic Oligomer HypothesisEndocrine Reviews, 2008
- Protein Misfolding, Functional Amyloid, and Human DiseaseAnnual Review of Biochemistry, 2006
- Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiologyBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2001
- Islet Amyloid Polypeptide (IAPP) A short reviewActa Oncologica, 1991
- Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.Proceedings of the National Academy of Sciences of the United States of America, 1987